The FDA said it will allow Colorado to import certain prescription drugs from Canada in an effort to bring prices down for residents.
The FDA said it will allow Colorado to import certain prescription drugs from Canada in an effort to bring prices down for residents.
A new analysis found that results for less than half of the clinical studies registered in a key European database were reported within the required time frame.
A syphilis drug shortage, Sanofi's diabetes drug approval, and more biotech news from The Readout
Trump administration revisits policy to plug Medicare drug price negotiation loophole.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow…
Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
Drug pricing in Europe, AI deals for VC firms, and more biotech news from The Readout
In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.
Plus a buried alcohol study gets published, and a Biosecure update.
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Google's making a move in the mosquito business.
Why did a presentation on Revolution Medicines' pancreatic cancer drug get a standing ovation? Why did biotech stocks perform so badly this week? Find out on "The Readout LOUD."
Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.
For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
Page 1
Older →